Holen Sie sich die Stockscreener-App
0.99
2.91%
0.028
Handel nachbörslich:
1.00
0.01
+1.01%
Nexalin Technology Inc Aktie (NXL) Neueste Nachrichten
Jane Street Group LLC Buys New Position in Nexalin Technology, Inc. (NASDAQ:NXL) - Defense World
Nexalin Technology closes partial over-allotment option By Investing.com - Investing.com Nigeria
Nexalin Technology closes partial over-allotment option - Investing.com
Nexalin Technology Closes Additional Share Offering - TipRanks
Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment - mx.advfn.com
Northern Trust Corp Makes New Investment in Nexalin Technology, Inc. (NASDAQ:NXL) - Defense World
Nexalin and FatPipe Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - IndyStar
Nexalin Technology, Inc.: Strategic Advancements and Financial Stability Justify Buy Rating - TipRanks
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on June 3 - GlobeNewswire
Nexalin Technology, Inc. to Host Investor Webinar Showcasing Innovative Neurostimulation Advances on June 3, 2025 - Nasdaq
Revolutionary Mental Health Tech: Nexalin Unveils Game-Changing Treatment in $537B Market Webinar - Stock Titan
Coming This Week: Get Ready for the ‘Last Wave of Negative News’ on Nvidia Stock - The Globe and Mail
Is This Dependable Growth Stock a Buy Right Now? - The Globe and Mail
Integrated Cyber Solutions Joins NVIDIA Connect Program to Accelerate Development of AI-Driven IC360 Cybersecurity Platform - The Globe and Mail
Clarifai Wins 2025 AI TechAward for Compute Orchestration - The Globe and Mail
Nexalin Technology earnings missed by $0.02, revenue topped estimates - Investing.com Canada
Nexalin Technology (NASDAQ:NXL) Shares Up 1.7% – Here’s Why - Defense World
Nexalin Technology slides after pricing $5M stock offering - MSN
Comparing Gadsden Properties (OTCMKTS:GADS) & Nexalin Technology (NASDAQ:NXL) - Defense World
Nexalin Technology Forms Scientific Advisory Board - citybiz
Nexalin Technology (NXL) Enhances Scientific Advisory Board to T - GuruFocus
Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer's Program Amid Encouraging Data - The Manila Times
Nexalin Technology Reconstitutes Scientific Advisory Board - GlobeNewswire
Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer’s Program Amid Encouraging Data - Stock Titan
Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering - Taiwan News
Nexalin Technology, Inc. Closes Public Offering of 3,850,000 Shares at $1.30 Per Share, Raising $5.0 Million - Nasdaq
Brain Tech Pioneer Nexalin Secures $5M Funding: 3.85M Shares at $1.30 in Public Offering - Stock Titan
Nexalin Technology Announces Public Offering Agreement - TipRanks
Form 424B4 Nexalin Technology, Inc. - StreetInsider
Nexalin Gains International Traction - ACCESS Newswire
Nexalin Shares Fall After Pricing of $5 Million Public Offering - marketscreener.com
Nexalin Technology (NXL) Announces Public Stock Offering | NXL S - GuruFocus
Nexalin Technology sets public offering at $1.30 per share - Investing.com Australia
Nexalin Prices 3.85 Mln Public Offering At $1.30/shr; Stock Plunges In Pre-market - Nasdaq
Nexalin Technology sets public offering at $1.30 per share By Investing.com - Investing.com India
Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock - GlobeNewswire
Nexalin Technology Prices $5 Million Public Offering - marketscreener.com
$5M Public Offering: How Nexalin Plans to Advance Revolutionary Brain Stimulation Technology - Stock Titan
SEC Form 424B5 filed by Nexalin Technology Inc. - Quantisnow
Nexalin Technology, Inc. (NASDAQ:NXL) Shares Acquired by Geode Capital Management LLC - Defense World
SEC Form 424B4 filed by Nexalin Technology Inc. - Quantisnow
Nexalin Technology (NXL) Seeks FDA Feedback for Gen-2 SYNC Syste - GuruFocus
Nexalin Technology Says Q-Submission To Facilitate Dialogue With FDA On Clinical Trial Design - marketscreener.com
Nexalin Technology, Inc. Plans Q-Submission to FDA for Gen-2 SYNC System Targeting Cognitive Disorders - Nasdaq
Nexalin Technology Initiates FDA Q-Submission Process for - GlobeNewswire
FDA Fast-Tracks Nexalin Gen-2 SYNC Review for Alzheimer's Treatment | NXL Stock News - Stock Titan
Nexalin Technology (NASDAQ:NXL) Shares Down 0.5% – Time to Sell? - Defense World
International Milestone for Anxiety-Insomnia Neurostim Company - Sleep Review
Nexalin Technology files $50M common stock offering - MSN
Nexalin Technology (NXL) Gains Approval for Clinical Trial in Br - GuruFocus
Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia - GlobeNewswire
0.32%
0.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):